Significant biosimilar activities this week include
01 May 2020 | AbbVie released its Q1 2020 financial results, reporting a 13.7% increase in US sales of Humira® (adalimumab) from Q1 2019. In global markets, Humira® sales were down 14.9%, a decline that was attributed to biosimilar competition.
04 May 2020 | Teva and Celltrion announced the launch of Truxima® (biosimilar rituximab) in the US. Truxima® is indicated for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis and miscroscopic polyangiitis.
06 May 2020 | Bausch + Lomb announced it has entered into an exclusive licensing agreement with STADA and Xbrane Biopharma for the development and commercialisation of a ranibizumab biosimilar. Under the agreement, Xbrane and STADA will be jointly responsible for finalising development of the biosimilar, with Xbrane to provide commercial supply and Bausch + Lomb responsible for sales, marketing and all other commercialisation efforts.
08 May 2020 | the American Journal of Medical Care published results of clinical trials of AryoGen’s BE1040V, biosimilar bevacizumab. Researchers reported the product was non-inferior to the reference product in terms of efficacy for the treatment of metastatic colorectal cancer.
08 May 2020 | Results of the Novartis’ EXCEED study comparing adalimumab and secukinumab for the treatment of PSA (psoriatic arthritis) were released. Researchers reported no statistically significant superiority between secukinumab and adalimumab as first-line treatment of psoriatic arthritis, but secukinumab was associated with a higher treatment retention rate than adalimumab.
Print Page Mail Article